Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Tele2 in the merger with Com Hem
Mandate

Vinge advises Tele2 in the merger with Com Hem

January 10, 2018 Capital Markets and Public M&A

Tele2 AB (publ) and Com Hem Holding AB (publ) announced on 10 January 2018 that they have agreed on a combination through a statutory merger in accordance with the Swedish Companies Act.

The combined company will be a leading integrated connectivity provider by combining an award-winning mobile network with the fastest national fixed network and the widest range of content in the market. The combination is conditional upon, inter alia, approval from the relevant competition authorities and approval of the merger from the shareholders in Tele2 and Com Hem. The merger is currently expected to be completed in the second half of 2018.

Vinge’s team primarily consists of Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Amanda Knutsson and Annika Nyberg Ekenberg (capital markets), Marcus Glader, Johan Karlsson, Emma Johansson, Grant McKelvey and Sebastian Örndahl (competition and regulatory), Louise Brorsson Salomon, Helena Håkansson and Lionardo Ojeda (financing) as well as Fredrik Dahl and Fredrik Gustafsson (employment).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025